Mpox Update for EMS Personnel
Share this article
Mpox: Transmission, Disease Severity, and Outbreaks
Mpox is a viral disease caused by infection with the Monkeypox virus (MPXV). There are two distinct genetic clades, clade I and clade II, which are endemic to central and west Africa, respectively.
Clade I MPXV can spread from human to human and is associated with more severe infections than clade II, which has been observed to be less virulent. Clade IIb MPXV was responsible for the 2022 global outbreak that predominately affected gay, bisexual, and other men who have sex with men (MSM). The order of virulence, meaning how sick the virus can make someone, is clade I > clade II > clade IIb.
Before the 2022 global outbreak, mpox was mostly confined to central and western African countries. Cases outside these regions were rare and typically linked to travel or animal imports from endemic areas.
Since January 1, 2023, the Democratic Republic of the Congo (DRC) has reported 12,569 suspected mpox cases and 581 deaths, largely attributed to clade I. The current threat for clade I MPXV in travelers to the U.S. is low, however, clinicians should be aware of the possibility of clade I MPXV in travelers who have been in DRC.
Meanwhile, clade IIb MPXV infections continue to occur in the United States (CDC, https://www.cdc.gov/mpox/data-research/cases/, Accessed 2025) and the CDC encourages U.S. clinicians to continue to be alert for patients presenting with lesions consistent with mpox (CDC, https://www.cdc.gov/mpox/hcp/clinical-signs/, Accessed 2025).
Prevention and Medical Countermeasures
Vaccines such as JYNNEOS and ACAM2000, and medical countermeasures including tecovirimat (TPOXX), brincidofovir, and vaccinia immune globulin intravenous, are available and effective for the prevention and treatment of MPXV infections, respectively, regardless of clade. However, vaccination coverage in the United States remains low. CDC recommends that clinicians encourage vaccination for eligible patients (CDC, https://www.cdc.gov/mpox/vaccines/, Accessed 2025).
Identify, Isolate, and Inform for EMS Personnel
It is very unlikely that EMS clinicians will encounter a person infected with clade I or clade II MPXV, the types endemic to central and west Africa, during routine operations. It is more likely that EMS clinicians will encounter a patient infected with clade IIb MPXV. All health care professionals should adhere to an identify, isolate, and inform strategy.
Identifying the Signs, Symptoms, and Risk Factors for Mpox
- Infection with MPXV begins with an incubation period where the person does not have symptoms and may feel fine. The incubation period is roughly 1-2 weeks. Some people can spread mpox to others from 1 to 4 days before they have symptoms.
- Symptoms may include fever, malaise, headache, sore throat, cough, and swollen lymph nodes. Lymphadenopathy is a characteristic feature of mpox, and lymph nodes may swell in the neck, armpits, or groin, and can occur on both sides of the body or just one. A person may be contagious during this period.
- One to three days after the onset of viral symptoms, patients will typically develop a rash that becomes vesicular/pustular starting on the face and spreading to the rest of the body. In clade IIb MPXV cases, people often have a rash without any other symptoms or have localized lesions instead of a diffuse rash. A person is contagious until after all the scabs on the skin have fallen off and a fresh layer of intact skin has formed underneath.
- EMS personnel should be alert for patients presenting with lesions consistent with mpox (CDC, https://www.cdc.gov/mpox/hcp/clinical-signs/, Accessed 2025) who have recently traveled to a country where mpox is endemic—or other areas reporting mpox cases—or had close contact with a person sick with mpox in the last 5-21 days.
Although most mpox infections are not life-threatening, some people may face a higher risk of severe illness, including:
- People with severely weakened immune systems
- Children younger than 1 year of age
- People with a history of eczema
- People who are pregnant
Isolation Guidelines for Mpox in EMS Settings
- A patient is considered infectious 5 days before rash onset until the crusting of skin lesions.
- MPXV can be transmitted through exposure to mucous membranes (eyes, nose, mouth), direct contact with body fluids or lesions, and indirect contact with lesions, such as through contaminated clothing or linens. Learn more about Mpox causes (CDC, https://www.cdc.gov/mpox/causes/, Accessed 2025).
- To guard against the possibility of MPXV transmission, EMS personnel should strictly adhere to standard, contact, and airborne precautions. This includes a NIOSH-approved, fit-tested N-95 respirator, gown, gloves, and eye protection with face shield or goggles. For more information on MPOX infection prevention and control, please see CDC’s information on Infection Control: Healthcare Settings (CDC, https://www.cdc.gov/monkeypox/hcp/infection-control/healthcare-settings.html, Accessed 2025).
Implementing a Hierarchy of Controls in EMS Care
- Separate the driver compartment from the patient compartment.
- Turn the exhaust fan on high in the patient compartment, if so equipped.
- Adjust air handling to introduce fresh air in both compartments if possible.
- The driver of the ambulance should wear an N-95 respirator if isolation of the driver compartment cannot be verified.
- Limit the number of personnel making patient contact.
- Use PPE checklists for donning and doffing, ideally with a trained observer. See NETEC’s guide on the role of the trained observer.
- Exercise caution when performing aerosol-generating procedures, e.g., endotracheal intubation, airway suctioning, CPAP/BiPAP, and CPR. Only perform these procedures if medically necessary and cannot be postponed. Clean and disinfect all surfaces of the ambulance and equipment with an EPA-registered hospital-grade disinfectant with an emerging viral pathogen claim. Products with Emerging Viral Pathogens claims may be found on EPA’s List Q. Follow the manufacturer’s directions for concentration, contact time, and care and handling.
Infection Prevention and Waste Management When Caring for a Patient with Mpox
- Apply a mask to the patient for source control if tolerated and consider covering affected areas of the patient’s skin with an impervious sheet if a rash is present.
- Monitor personnel for signs and symptoms of illness for 21 days after transport if the patient is confirmed to have mpox.
- More guidance can be found in the EMS Infectious Disease Playbook in the “Special Respiratory Precautions” section.
- New guidance from the Department of Transportation has been published (Planning Guidance for Handling Category A Solid Waste | PHMSA (dot.gov)), clarifying that clinical waste containing MPVX clade I or II or IIb can be designated as Category B infectious substances, meaning it requires the same precautions typical for other medical waste. Before this update, clade I materials were designated as Category A infectious substances. Note that clade I MPXV remains a Select Agent, and may have additional requirements. Learn more about Mpox waste guidance.
- See the Department of Transportation website for more information. Facilities should also comply with state and local regulations (Hercenter, Accessed 2025, https://www.hercenter.org/rmw/rmwlocator.php) for handling, storage, treatment, and disposal of waste. (CDC, https://www.cdc.gov/mpox/hcp/infection-control/healthcare-settings.html, Accessed 2025)
Informing Health Care Personnel and Public Health Authorities of a Suspected Case of Mpox
- EMS personnel should notify their state health department if they have a patient with mpox-like symptoms (CDC, https://www.cdc.gov/mpox/signs-symptoms/, Accessed 2025) for possible initiation of special pathogen transport protocols.
- Inform other responding personnel if a risk of mpox is suspected and prevent unprotected exposure to the patient.
- Inform supervisory personnel – some communities may have dedicated transport teams and/or designated facilities for transport and management of patients suspected or confirmed to be infected with special pathogens.
- Inform the receiving facility, as soon as possible, of a patient that may have mpox, so that space is made available to properly isolate the patient on arrival (airborne isolation room if available) and that receiving health care personnel are wearing appropriate PPE.
Get Expert Assistance
Ask a NETEC expert a question or request free services for your facility.
Find Resources
Explore special pathogen resources created and curated by NETEC experts.
